Oral Diseases, Journal Year: 2024, Volume and Issue: unknown
Published: May 19, 2024
Language: Английский
Oral Diseases, Journal Year: 2024, Volume and Issue: unknown
Published: May 19, 2024
Language: Английский
Journal of Dental Sciences, Journal Year: 2025, Volume and Issue: 20(2), P. 1252 - 1256
Published: Jan. 18, 2025
Burning mouth syndrome (BMS) is a chronic condition characterized by intraoral burning sensation and orofacial pain but without oral mucosal lesions. The purpose of this study was to analyze the scientometric characteristics research trends BMS. All papers on BMS were comprehensively retrieved from Scopus database. years publication divided into before 2015 2015-2024 in analysis trends. There 924 BMS, with total citations 24,024 h index 76. related disorders depression, xerostomia, pain, anxiety, glossodynia, taste disorder, nociception, paresthesia, analgesia, sleep diabetes mellitus, neuralgia. Clonazepam most common pharmacotherapy for After 2015, pharmacologic keywords including drug safety, aripiprazole, duloxetine, folic acid, hydrocortisone, pregabalin more frequent. Low level laser therapy, acupuncture, cognitive behavioral therapy emerging nonpharmacologic strategies Moreover, laboratory investigations biomarkers, blood, genetics, interleukin 6, tumor necrosis factor common. Various questionnaires, comorbidity, complication, anemia, hypertension, also concerned after 2015. This elucidated current scenario would help improving reciprocal collaboration communication condition.
Language: Английский
Citations
0BMC Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: April 6, 2025
The prevalence of burning mouth syndrome (BMS) is approximately 8% in clinical patients; thus, BMS remains a therapeutic challenge. Photobiomodulation (PBM) and oral cryotherapy (OCT) have been evaluated for the treatment pain, but no confirmatory trials performed. To evaluate comparative effectiveness PBM combined with OCT at reducing pain psychological distress compared alone, or drug therapy (DT) alone cohort patients BMS. This multi-institutional, single-blinded (assessor-blinded), randomized controlled trial 4 groups was conducted Xinhua Hospital, Shanghai Jiao Tong University School Medicine Affiliated Stomatology Hospital Guilin Medical from December 12, 2022, to January 24, 2024. Among 156 assessed eligibility, 28 were excluded, 128 qualified randomization 1 groups. participants received 7 sessions (1) OCT, (2) PBM, (3) (4) DT during 7-week period. coprimary outcome measures changes visual analogue scale (VAS) scores overall response rate between baseline weeks treatment. After treatment, + group achieved high reduction (81.25%). difference trends resulted nearly fivefold greater mean change VAS score 12-week assessment than (p < 0.0083). Furthermore, anxiety symptoms also significantly alleviated by resulting tenfold GAD-7 No severe adverse events reported study combination reduces mucosa alleviates BMS; this expected become promising management option Chinese Clinical Trial Registry Identifier: ChiCTR2300074518.
Language: Английский
Citations
0Oral Diseases, Journal Year: 2024, Volume and Issue: 30(8), P. 5496 - 5497
Published: May 12, 2024
Language: Английский
Citations
1Oral, Journal Year: 2024, Volume and Issue: 4(3), P. 376 - 385
Published: Sept. 4, 2024
Background: Burning mouth syndrome (BMS) is a chronic condition characterized by an intractable burning sensation in the oral cavity without visible mucosal lesions. Current treatment options are diverse but often limited variable efficacy and patient tolerance. This study aimed to evaluate of turmeric combined with vitamin B6 (pyridoxine HCl) treating BMS. Methods: In this retrospective, single-arm study, 28 non-smoking female patients BMS were treated daily regimen for 60 days. The pain intensity was assessed using visual analog scale (VAS) before initiation (baseline VAS, BVAS) after period (final FVAS). Wilcoxon signed-rank test utilized analyze changes VAS scores. Results: mean BVAS score 5.61 (SD = 1.87), indicating moderate at baseline. Post-treatment, FVAS significantly decreased 2.14 1.35). median delta scores demonstrated substantial reduction (median 4.0; 3.46; SD 2.05). Statistical analyses revealed significant (W 0.0, p < 0.0001). Conclusions: combination found reduce BMS, therapeutic approach may be promising alternative management. Larger-scale clinical trials warranted further validate these findings.
Language: Английский
Citations
1International Dental Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 1, 2024
Language: Английский
Citations
1Frontiers in Oral Health, Journal Year: 2024, Volume and Issue: 5
Published: Dec. 18, 2024
Burning mouth syndrome (BMS) is a chronic orofacial pain disorder that seriously affects quality of life patients. In recent years, Low-level laser therapy (LLLT) has been regarded as an important innovation in management, but there insufficient evidence its effectiveness patients with painful BMS. This study aimed to evaluate the efficacy LLLT for immediate relief due
Language: Английский
Citations
1Oral Diseases, Journal Year: 2024, Volume and Issue: unknown
Published: May 19, 2024
Language: Английский
Citations
0